3,4-Difluoroamphetamine

3,4-Difluoroamphetamine

3,4-Difluoroamphetamine

Designer drug of the substituted amphetamine class

3,4-Difluoroamphetamine (DFA) is a substituted amphetamine which has been sold as a designer drug. It has relatively weak activity as a serotonin releasing agent with only around 1/4 of the affinity for the serotonin transporter compared to MDA, but its activity at other targets has not been studied.[1][2]

Quick Facts Identifiers, CAS Number ...

See also

References

  1. [1]
    Roman DL, Saldaña SN, Nichols DE, Carroll FI, Barker EL (February 2004). "Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters". The Journal of Pharmacology and Experimental Therapeutics. 308 (2): 679–687. doi:10.1124/jpet.103.057836. PMID 14593087. S2CID 6439942.
  2. [2]
    Walline CC, Nichols DE, Carroll FI, Barker EL (June 2008). "Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition". The Journal of Pharmacology and Experimental Therapeutics. 325 (3): 791–800. doi:10.1124/jpet.108.136200. PMC 2637348. PMID 18354055.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article 3,4-Difluoroamphetamine, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.